1
|
Van Kolen K, Malia TJ, Theunis C, Nanjunda R, Teplyakov A, Ernst R, Wu SJ, Luo J, Borgers M, Vandermeeren M, Bottelbergs A, Wintmolders C, Lacy E, Maurin H, Larsen P, Willems R, Van De Casteele T, Triana-Baltzer G, Slemmon R, Galpern W, Trojanowski JQ, Sun H, Mercken MH. Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody. J Alzheimers Dis 2021; 77:1397-1416. [PMID: 32894244 DOI: 10.3233/jad-200544] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
BACKGROUND As a consequence of the discovery of an extracellular component responsible for the progression of tau pathology, tau immunotherapy is being extensively explored in both preclinical and clinical studies as a disease modifying strategy for the treatment of Alzheimer's disease. OBJECTIVE Describe the characteristics of the anti-phospho (T212/T217) tau selective antibody PT3 and its humanized variant hPT3. METHODS By performing different immunization campaigns, a large collection of antibodies has been generated and prioritized. In depth, in vitro characterization using surface plasmon resonance, phospho-epitope mapping, and X-ray crystallography experiments were performed. Further characterization involved immunohistochemical staining on mouse- and human postmortem tissue and neutralization of tau seeding by immunodepletion assays. RESULTS AND CONCLUSION Various in vitro experiments demonstrated a high intrinsic affinity for PT3 and hPT3 for AD brain-derived paired helical filaments but also to non-aggregated phospho (T212/T217) tau. Further functional analyses in cellular and in vivo models of tau seeding demonstrated almost complete depletion of tau seeds in an AD brain homogenate. Ongoing trials will provide the clinical evaluation of the tau spreading hypothesis in Alzheimer's disease.
Collapse
Affiliation(s)
- Kristof Van Kolen
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Thomas J Malia
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Clara Theunis
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Rupesh Nanjunda
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Alexey Teplyakov
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Robin Ernst
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Sheng-Jiun Wu
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Jinquan Luo
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Marianne Borgers
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Marc Vandermeeren
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Astrid Bottelbergs
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Cindy Wintmolders
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Eilyn Lacy
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Hervé Maurin
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Peter Larsen
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Roland Willems
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Tom Van De Casteele
- Translational Medicine and Early Development Statistics Janssen Research & Development, Beerse, Belgium
| | | | - Randy Slemmon
- Neuroscience biomarkers, Janssen Research & Development, La Jolla, CA, USA
| | - Wendy Galpern
- Neuroscience Experimental medicine, Janssen Research & Development, Titusville, NJ, USA
| | | | - Hong Sun
- Neuroscience Clinical Development, Janssen Research & Development, Titusville, NJ, USA
| | - Marc H Mercken
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| |
Collapse
|
2
|
Vandermeeren M, Borgers M, Van Kolen K, Theunis C, Vasconcelos B, Bottelbergs A, Wintmolders C, Daneels G, Willems R, Dockx K, Delbroek L, Marreiro A, Ver Donck L, Sousa C, Nanjunda R, Lacy E, Van De Casteele T, Van Dam D, De Deyn PP, Kemp JA, Malia TJ, Mercken MH. Anti-Tau Monoclonal Antibodies Derived from Soluble and Filamentous Tau Show Diverse Functional Properties in vitro and in vivo. J Alzheimers Dis 2019; 65:265-281. [PMID: 30040731 DOI: 10.3233/jad-180404] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The tau spreading hypothesis provides rationale for passive immunization with an anti-tau monoclonal antibody to block seeding by extracellular tau aggregates as a disease-modifying strategy for the treatment of Alzheimer's disease (AD) and potentially other tauopathies. As the biochemical and biophysical properties of the tau species responsible for the spatio-temporal sequences of seeding events are poorly defined, it is not yet clear which epitope is preferred for obtaining optimal therapeutic efficacy. Our internal tau antibody collection has been generated by immunizations with different tau species: aggregated- and non-aggregated tau and human postmortem AD brain-derived tau fibrils. In this communication, we describe and characterize a set of these anti-tau antibodies for their biochemical and biophysical properties, including binding, tissue staining by immunohistochemistry, and epitope. The antibodies bound to different domains of the tau protein and some were demonstrated to be isoform-selective (PT18 and hTau56) or phospho-selective (PT84). Evaluation of the antibodies in cellular- and in vivo seeding assays revealed clear differences in maximal efficacy. Limited proteolysis experiments support the hypothesis that some epitopes are more exposed than others in the tau seeds. Moreover, antibody efficacy seems to depend on the structural properties of fibrils purified from tau Tg mice- and postmortem human AD brain.
Collapse
Affiliation(s)
- Marc Vandermeeren
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Marianne Borgers
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Kristof Van Kolen
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Clara Theunis
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Bruno Vasconcelos
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Astrid Bottelbergs
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Cindy Wintmolders
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Guy Daneels
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Roland Willems
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Koen Dockx
- Discovery Sciences, Janssen Research and Development, Beerse, Belgium
| | - Lore Delbroek
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - André Marreiro
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Luc Ver Donck
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Cristiano Sousa
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| | - Rupesh Nanjunda
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Eilyn Lacy
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | | | - Debby Van Dam
- Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.,Department of Neurology and Alzheimer Research Center, University Medical Center Groningen (UMCG), Groningen, The Netherlands
| | - Peter Paul De Deyn
- Laboratory of Neurochemistry and Behavior, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.,Department of Neurology and Alzheimer Research Center, University Medical Center Groningen (UMCG), Groningen, The Netherlands.,Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoge Beuken, Antwerp, Belgium.,Biobank, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium
| | - John A Kemp
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium.,Syndesi therapeutics, Belgium
| | - Thomas J Malia
- Biologics Research, Janssen Research and Development, Spring House, PA, USA
| | - Marc H Mercken
- Neuroscience Department, Janssen Research and Development, Beerse, Belgium
| |
Collapse
|
3
|
Teplyakov A, Obmolova G, Malia TJ, Raghunathan G, Martinez C, Fransson J, Edwards W, Connor J, Husovsky M, Beck H, Chi E, Fenton S, Zhou H, Almagro JC, Gilliland GL. Structural insights into humanization of anti-tissue factor antibody 10H10. MAbs 2018; 10:269-277. [PMID: 29283291 PMCID: PMC5825201 DOI: 10.1080/19420862.2017.1412026] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Murine antibody 10H10 raised against human tissue factor is unique in that it blocks the signaling pathway, and thus inhibits angiogenesis and tumor growth without interfering with coagulation. As a potential therapeutic, the antibody was humanized in a two-step procedure. Antigen-binding loops were grafted onto selected human frameworks and the resulting chimeric antibody was subjected to affinity maturation by using phage display libraries. The results of humanization were analyzed from the structural perspective through comparison of the structure of a humanized variant with the parental mouse antibody. This analysis revealed several hot spots in the framework region that appear to affect antigen binding, and therefore should be considered in human germline selection. In addition, some positions in the Vernier zone, e.g., residue 71 in the heavy chain, that are traditionally thought to be crucial appear to tolerate amino acid substitutions without any effect on binding. Several humanized variants were produced using both short and long forms of complementarity-determining region (CDR) H2 following the difference in the Kabat and Martin definitions. Comparison of such pairs indicated consistently higher thermostability of the variants with short CDR H2. Analysis of the binding data in relation to the structures singled out the ImMunoGeneTics information system® germline IGHV1-2*01 as dubious owing to two potentially destabilizing mutations as compared to the other alleles of the same germline and to other human germlines.
Collapse
Affiliation(s)
- Alexey Teplyakov
- a Janssen Research and Development, LLC , 1400 McKean Road, Spring House, PA , USA
| | - Galina Obmolova
- a Janssen Research and Development, LLC , 1400 McKean Road, Spring House, PA , USA
| | - Thomas J Malia
- a Janssen Research and Development, LLC , 1400 McKean Road, Spring House, PA , USA
| | - Gopalan Raghunathan
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Christian Martinez
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Johan Fransson
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Wilson Edwards
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Judith Connor
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Matthew Husovsky
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Heena Beck
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Ellen Chi
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Sandra Fenton
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Hong Zhou
- b Janssen Research and Development, LLC , 3210 Merryfield Row, San Diego , CA , USA
| | - Juan Carlos Almagro
- a Janssen Research and Development, LLC , 1400 McKean Road, Spring House, PA , USA
| | - Gary L Gilliland
- a Janssen Research and Development, LLC , 1400 McKean Road, Spring House, PA , USA
| |
Collapse
|
4
|
Teplyakov A, Obmolova G, Malia TJ, Gilliland GL. Crystal structure of CD27 in complex with a neutralizing noncompeting antibody. Acta Crystallogr F Struct Biol Commun 2017; 73:294-299. [PMID: 28471362 PMCID: PMC5417320 DOI: 10.1107/s2053230x17005957] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 04/19/2017] [Indexed: 11/21/2022] Open
Abstract
CD27 is a T-cell and B-cell co-stimulatory glycoprotein of the tumor necrosis factor (TNF) receptor superfamily that is dependent on the availability of the TNF-like ligand CD70. Therapeutic approaches to treating autoimmune diseases and cancers with antagonistic and agonistic anti-CD27 monoclonal antibodies (mAbs), respectively, have recently been developed. Mouse anti-human CD27 mAb 2177 shows potency in neutralizing CD70-induced signaling; however, it does not block the binding of soluble CD70. To provide insight into the mechanism of action of the mAb, the crystal structure of the CD27 extracellular domain in complex with the Fab fragment of mAb 2177 was determined at 1.8 Å resolution. CD27 exhibits the assembly of cysteine-rich domains characteristic of the TNF receptor superfamily. The structure reveals a unique binding site of mAb 2177 at the edge of the receptor molecule, which allows the mAb to sterically block the cell-bound form of CD70 from reaching CD27 while leaving the ligand epitope clear. This mode of action suggests a potential dual use of mAb 2177 either as an antagonist or as an agonist.
Collapse
MESH Headings
- Amino Acid Motifs
- Animals
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/genetics
- Antibodies, Neutralizing/chemistry
- Antibodies, Neutralizing/genetics
- Antigen-Antibody Complex/chemistry
- Antigen-Antibody Complex/genetics
- Baculoviridae/genetics
- Baculoviridae/metabolism
- Binding Sites
- CD27 Ligand/chemistry
- CD27 Ligand/genetics
- CD27 Ligand/immunology
- Cloning, Molecular
- Crystallography, X-Ray
- Gene Expression
- Genetic Vectors/chemistry
- Genetic Vectors/metabolism
- HEK293 Cells
- Humans
- Immunoglobulin Fab Fragments/chemistry
- Immunoglobulin Fab Fragments/genetics
- Ligands
- Mice
- Models, Molecular
- Protein Binding
- Protein Conformation, beta-Strand
- Protein Interaction Domains and Motifs
- Recombinant Fusion Proteins/chemistry
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Sequence Alignment
- Sf9 Cells
- Spodoptera
- Tumor Necrosis Factor Receptor Superfamily, Member 7/chemistry
- Tumor Necrosis Factor Receptor Superfamily, Member 7/genetics
- Tumor Necrosis Factor Receptor Superfamily, Member 7/immunology
Collapse
Affiliation(s)
- Alexey Teplyakov
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Galina Obmolova
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Thomas J. Malia
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Gary L. Gilliland
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| |
Collapse
|
5
|
Teplyakov A, Malia TJ, Obmolova G, Jacobs SA, O'Neil KT, Gilliland GL. Conformational flexibility of an anti-IL-13 DARPin†. Protein Eng Des Sel 2016; 30:31-37. [PMID: 27881684 DOI: 10.1093/protein/gzw059] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Revised: 09/24/2016] [Accepted: 10/20/2016] [Indexed: 01/29/2023] Open
Abstract
Designed ankyrin repeat proteins (DARPin®) are artificial non-immunoglobulin binding proteins with potential applications as therapeutic molecules. DARPin 6G9 binds interleukin-13 with high affinity and blocks the signaling pathway and as such is promising for the treatment of asthma and other atopic diseases. The crystal structures of DARPin 6G9 in the unbound form and in complex with IL-13 were determined at high resolution. The DARPin competes for the same epitope as the IL-13 receptor chain 13Rα1 but does not interfere with the binding of the other receptor chain, IL-4Rα. Analysis of multiple copies of the DARPin molecule in the crystal indicates the conformational instability in the N-terminal cap that was predicted from molecular dynamics simulations. Comparison of the DARPin structures in the free state and in complex with IL-13 reveals a concerted movement of the ankyrin repeats upon binding resulted in the opening of the binding site. The induced-fit mode of binding employed by DARPin 6G9 is very unusual for DARPins since they were designed as particularly stable and rigid molecules. This finding shows that DARPins can operate by various binding mechanisms and suggests that some flexibility in the scaffold may be an advantage.
Collapse
Affiliation(s)
- Alexey Teplyakov
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Thomas J Malia
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Galina Obmolova
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Steven A Jacobs
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Karyn T O'Neil
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Gary L Gilliland
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, USA
| |
Collapse
|
6
|
Abstract
To support antibody therapeutic development, the crystal structures of a set of 16 germline variants composed of 4 different kappa light chains paired with 4 different heavy chains have been determined. All four heavy chains of the antigen-binding fragments (Fabs) have the same complementarity-determining region (CDR) H3 that was reported in an earlier Fab structure. The structure analyses include comparisons of the overall structures, canonical structures of the CDRs and the VH:VL packing interactions. The CDR conformations for the most part are tightly clustered, especially for the ones with shorter lengths. The longer CDRs with tandem glycines or serines have more conformational diversity than the others. CDR H3, despite having the same amino acid sequence, exhibits the largest conformational diversity. About half of the structures have CDR H3 conformations similar to that of the parent; the others diverge significantly. One conclusion is that the CDR H3 conformations are influenced by both their amino acid sequence and their structural environment determined by the heavy and light chain pairing. The stem regions of 14 of the variant pairs are in the ‘kinked’ conformation, and only 2 are in the extended conformation. The packing of the VH and VL domains is consistent with our knowledge of antibody structure, and the tilt angles between these domains cover a range of 11 degrees. Two of 16 structures showed particularly large variations in the tilt angles when compared with the other pairings. The structures and their analyses provide a rich foundation for future antibody modeling and engineering efforts.
Collapse
Affiliation(s)
| | - Galina Obmolova
- a Janssen Research & Development LLC, Spring House , PA , USA
| | - Thomas J Malia
- a Janssen Research & Development LLC, Spring House , PA , USA
| | - Jinquan Luo
- a Janssen Research & Development LLC, Spring House , PA , USA
| | - Salman Muzammil
- a Janssen Research & Development LLC, Spring House , PA , USA
| | - Raymond Sweet
- a Janssen Research & Development LLC, Spring House , PA , USA
| | | | | |
Collapse
|
7
|
Malia TJ, Teplyakov A, Ernst R, Wu SJ, Lacy ER, Liu X, Vandermeeren M, Mercken M, Luo J, Sweet RW, Gilliland GL. Epitope mapping and structural basis for the recognition of phosphorylated tau by the anti-tau antibody AT8. Proteins 2016; 84:427-34. [PMID: 26800003 PMCID: PMC5067699 DOI: 10.1002/prot.24988] [Citation(s) in RCA: 69] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2015] [Revised: 12/14/2015] [Accepted: 12/19/2015] [Indexed: 11/09/2022]
Abstract
Microtubule‐associated protein tau becomes abnormally phosphorylated in Alzheimer's disease and other tauopathies and forms aggregates of paired helical filaments (PHF‐tau). AT8 is a PHF‐tau‐specific monoclonal antibody that is a commonly used marker of neuropathology because of its recognition of abnormally phosphorylated tau. Previous reports described the AT8 epitope to include pS202/pT205. Our studies support and extend previous findings by also identifying pS208 as part of the binding epitope. We characterized the phosphoepitope of AT8 through both peptide binding studies and costructures with phosphopeptides. From the cocrystal structure of AT8 Fab with the diphosphorylated (pS202/pT205) peptide, it appeared that an additional phosphorylation at S208 would also be accommodated by AT8. Phosphopeptide binding studies showed that AT8 bound to the triply phosphorylated tau peptide (pS202/pT205/pS208) 30‐fold stronger than to the pS202/pT205 peptide, supporting the role of pS208 in AT8 recognition. We also show that the binding kinetics of the triply phosphorylated peptide pS202/pT205/pS208 was remarkably similar to that of PHF‐tau. The costructure of AT8 Fab with a pS202/pT205/pS208 peptide shows that the interaction interface involves all six CDRs and tau residues 202–209. All three phosphorylation sites are recognized by AT8, with pT205 acting as the anchor. Crystallization of the Fab/peptide complex under acidic conditions shows that CDR‐L2 is prone to unfolding and precludes peptide binding, and may suggest a general instability in the antibody. Proteins 2016; 84:427–434. © 2016 The Authors. Proteins: Structure, Function, and Bioinformatics Published by Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Thomas J Malia
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Alexey Teplyakov
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Robin Ernst
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Sheng-Jiun Wu
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Eilyn R Lacy
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Xuesong Liu
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Marc Vandermeeren
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Marc Mercken
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Jinquan Luo
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Raymond W Sweet
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | - Gary L Gilliland
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| |
Collapse
|
8
|
Obmolova G, Teplyakov A, Malia TJ, Keough E, Luo J, Sweet R, Jacobs SA, Yi F, Hippensteel R, O'Neil KT, Gilliland GL. Induced conformational change in human IL-4 upon binding of a signal-neutralizing DARPin. Proteins 2015; 83:1191-7. [PMID: 25900776 PMCID: PMC5029753 DOI: 10.1002/prot.24815] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Revised: 04/08/2015] [Accepted: 04/11/2015] [Indexed: 11/12/2022]
Abstract
The crystal structure of DARPin 44C12V5 that neutralizes IL-4 signaling has been determined alone and bound to human IL-4. A significant conformational change occurs in the IL-4 upon DARPin binding. The DARPin binds to the face of IL-4 formed by the A and C α-helices. The structure of the DARPin remains virtually unchanged. The conformational changes in IL-4 include a reorientation of the C-helix Trp91 side chain and repositioning of CD-loop residue Leu96. Both side chains move by >9 Å, becoming buried in the central hydrophobic region of the IL-4:DARPin interface. This hydrophobic region is surrounded by a ring of hydrophilic interactions comprised of hydrogen bonds and salt bridges and represents a classical "hotspot." The structures also reveal how the DARPin neutralizes IL-4 signaling. Comparing the IL-4:DARPin complex structure with the structures of IL-4 bound to its receptors (Hage et al., Cell 1999; 97, 271-281; La Porte et al., Cell 2008, 132, 259-272), it is found that the DARPin binds to the same IL-4 face that interacts with the junction of the D1 and D2 domains of the IL-4Rα receptors. Signaling is blocked since IL-4 cannot bind to this receptor, which it must do first before initiating a productive receptor complex with either the IL-13α1 or the γc receptor.
Collapse
Affiliation(s)
- Galina Obmolova
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Alexey Teplyakov
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Thomas J. Malia
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Edward Keough
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Jinquan Luo
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Raymond Sweet
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
- Present address: Raymond Sweet's current address is 700 Oak Springs Rd.Bryn MawrPA19010
| | - Steven A. Jacobs
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Fang Yi
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Randi Hippensteel
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
- Present address: Randi Hippensteel's current address is Eurofins Lancaster Laboratories2425 New Holland PikeLancasterPA17601
| | - Karyn T. O'Neil
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| | - Gary L. Gilliland
- Janssen Research & Development, LLC, Biotechnology Center of ExcellenceSpring HousePennsylvania19477
| |
Collapse
|
9
|
Obmolova G, Malia TJ, Teplyakov A, Sweet RW, Gilliland GL. Protein crystallization with microseed matrix screening: application to human germline antibody Fabs. Acta Crystallogr F Struct Biol Commun 2014; 70:1107-15. [PMID: 25084393 PMCID: PMC4118815 DOI: 10.1107/s2053230x14012552] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2014] [Accepted: 05/30/2014] [Indexed: 11/10/2022] Open
Abstract
The crystallization of 16 human antibody Fab fragments constructed from all pairs of four different heavy chains and four different light chains was enabled by employing microseed matrix screening (MMS). In initial screening, diffraction-quality crystals were obtained for only three Fabs, while many Fabs produced hits that required optimization. Application of MMS, using the initial screens and/or refinement screens, resulted in diffraction-quality crystals of these Fabs. Five Fabs that failed to give hits in the initial screen were crystallized by cross-seeding MMS followed by MMS optimization. The crystallization protocols and strategies that resulted in structure determination of all 16 Fabs are presented. These results illustrate the power of MMS and provide a basis for developing future strategies for macromolecular crystallization.
Collapse
Affiliation(s)
- Galina Obmolova
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Thomas J. Malia
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Alexey Teplyakov
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Raymond W. Sweet
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| | - Gary L. Gilliland
- Janssen Research and Development LLC, 1400 McKean Road, Spring House, PA 19477, USA
| |
Collapse
|
10
|
Malia TJ, Teplyakov A, Brezski RJ, Luo J, Kinder M, Sweet RW, Almagro JC, Jordan RE, Gilliland GL. Structure and specificity of an antibody targeting a proteolytically cleaved IgG hinge. Proteins 2014; 82:1656-67. [PMID: 24638881 DOI: 10.1002/prot.24545] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2013] [Revised: 02/13/2014] [Accepted: 02/20/2014] [Indexed: 11/09/2022]
Abstract
The functional role of human antihinge (HAH) autoantibodies in normal health and disease remains elusive, but recent evidence supports their role in the host response to IgG cleavage by proteases that are prevalent in certain disorders. Characterization and potential exploitation of these HAH antibodies has been hindered by the absence of monoclonal reagents. 2095-2 is a rabbit monoclonal antibody targeting the IdeS-cleaved hinge of human IgG1. We have determined the crystal structure of the Fab of 2095-2 and its complex with a hinge analog peptide. The antibody is selective for the C-terminally cleaved hinge ending in G236 and this interaction involves an uncommon disulfide in VL CDR3. We probed the importance of the disulfide in VL CDR3 through engineering variants. We identified one variant, QAA, which does not require the disulfide for biological activity or peptide binding. The structure of this variant offers a starting point for further engineering of 2095-2 with the same specificity, but lacking the potential manufacturing liability of an additional disulfide. Proteins 2014; 82:1656-1667. © 2014 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Thomas J Malia
- Biologics Research, Janssen Research and Development, LLC, Spring House, Pennsylvania
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Teplyakov A, Luo J, Obmolova G, Malia TJ, Sweet R, Stanfield RL, Kodangattil S, Almagro JC, Gilliland GL. Antibody modeling assessment II. Structures and models. Proteins 2014; 82:1563-82. [PMID: 24633955 DOI: 10.1002/prot.24554] [Citation(s) in RCA: 54] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2013] [Revised: 02/23/2014] [Accepted: 03/06/2014] [Indexed: 12/12/2022]
Abstract
To assess the state-of-the-art in antibody structure modeling, a blinded study was conducted. Eleven unpublished Fab crystal structures were used as a benchmark to compare Fv models generated by seven structure prediction methodologies. In the first round, each participant submitted three non-ranked complete Fv models for each target. In the second round, CDR-H3 modeling was performed in the context of the correct environment provided by the crystal structures with CDR-H3 removed. In this report we describe the reference structures and present our assessment of the models. Some of the essential sources of errors in the predictions were traced to the selection of the structure template, both in terms of the CDR canonical structures and VL/VH packing. On top of this, the errors present in the Protein Data Bank structures were sometimes propagated in the current models, which emphasized the need for the curated structural database devoid of errors. Modeling non-canonical structures, including CDR-H3, remains the biggest challenge for antibody structure prediction.
Collapse
Affiliation(s)
- Alexey Teplyakov
- Janssen Research & Development, LLC, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Teplyakov A, Obmolova G, Malia TJ, Luo J, Gilliland GL. Structural evidence for a constrained conformation of short CDR-L3 in antibodies. Proteins 2014; 82:1679-83. [PMID: 24470236 DOI: 10.1002/prot.24522] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2013] [Revised: 12/29/2013] [Accepted: 01/16/2014] [Indexed: 11/11/2022]
Abstract
Three Fab structures used as targets in the Antibody Modeling Assessment presented a challenge for modeling CDR-L3 due to deviations from the most typical canonical structure. In all three antibodies CDR-L3 has eight residues, which is one residue shorter than usual, and has a conformation that is rarely observed in crystal structures. We analyzed the sequence and structural determinants of this conformation and found that the "short" CDR-L3 is remarkably rigid and retains the conformation in the interactions with antigens and neighboring CDRs.
Collapse
Affiliation(s)
- Alexey Teplyakov
- Janssen Research & Development, LLC, Spring House, Pennsylvania, 19477
| | | | | | | | | |
Collapse
|
13
|
Luo J, Teplyakov A, Obmolova G, Malia TJ, Chan W, Jacobs SA, O'Neil KT, Gilliland GL. N-terminal β-strand swapping in a consensus-derived alternative scaffold driven by stabilizing hydrophobic interactions. Proteins 2014; 82:1527-33. [PMID: 24464739 DOI: 10.1002/prot.24517] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Revised: 01/09/2014] [Accepted: 01/16/2014] [Indexed: 11/08/2022]
Abstract
The crystal structure of an N-terminal β-strand-swapped consensus-derived tenascin FN3 alternative scaffold has been determined. A comparison with the unswapped structure reveals that the side chain of residue F88 orients differently and packs more tightly with the hydrophobic core of the domain. Dimer formation also results in the burial of a hydrophobic patch on the surface of the domain. Thus, it appears that tighter packing of F88 in the hydrophobic core and burial of surface hydrophobicity provide the driving forces for the N-terminal β-strand swapping, leading to the formation of a stable compact dimer.
Collapse
Affiliation(s)
- Jinquan Luo
- Biotechnology Center of Excellence, Janssen Research & Development LLC, Spring House, Pennsylvania, 19477
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Teplyakov A, Obmolova G, Malia TJ, Luo J, Jacobs SA, Chan W, Domingo D, Baker A, O'Neil KT, Gilliland GL. C-terminal β-strand swapping in a consensus-derived fibronectin Type III scaffold. Proteins 2014; 82:1359-69. [PMID: 24375666 DOI: 10.1002/prot.24502] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2013] [Revised: 12/09/2013] [Accepted: 12/17/2013] [Indexed: 11/07/2022]
Abstract
The crystal structures of six different fibronectin Type III consensus-derived Tencon domains, whose solution properties exhibit no, to various degrees of, aggregation according to SEC, have been determined. The structures of the five variants showing aggregation reveal 3D domain swapped dimers. In all five cases, the swapping involves the C-terminal β-strand resulting in the formation of Tencon dimers in which the target-binding surface is blocked. All of the variants differ in sequence in the FG loop, which is the hinge loop in the β-strand-swapped dimers. The six tencon variants have between 0 and 5 residues inserted between positions 77 and 78 in the FG loop. Analysis of the structures suggests that a non-glycine residue at position 77 and insertions of <4 residues may destabilize the β-turn in the FG loop promoting β-strand swapping. Swapped dimers with an odd number of inserted residues may be less stable, particularly if they contain proline residues, because they cannot form perfect β-bridges in the FG regions that link the swapped dimers. The Tencon β-swapped variants with the longest FG sequences are observed to form higher order hexameric or helical oligomeric structures in the crystal correlating well with the aggregation properties of these domains observed in solution. Understanding the structural basis for domain-swapped dimerization and oligomerization will support engineering efforts of the Tencon domain to produce variants with desired biophysical properties.
Collapse
Affiliation(s)
- Alexey Teplyakov
- Janssen Research & Development, LLC, Biotechnology Center of Excellence, 1400 McKean Road, Spring House, Pennsylvania, 19477
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Vafa O, Gilliland GL, Brezski RJ, Strake B, Wilkinson T, Lacy ER, Scallon B, Teplyakov A, Malia TJ, Strohl WR. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations. Methods 2013; 65:114-26. [PMID: 23872058 DOI: 10.1016/j.ymeth.2013.06.035] [Citation(s) in RCA: 119] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2013] [Revised: 06/24/2013] [Accepted: 06/27/2013] [Indexed: 01/26/2023] Open
Abstract
The Fc variant of IgG2, designated as IgG2σ, was engineered with V234A/G237A /P238S/H268A/V309L/A330S/P331S substitutions to eliminate affinity for Fcγ receptors and C1q complement protein and consequently, immune effector functions. IgG2σ was compared to other previously well-characterized Fc 'muted' variants, including aglycosylated IgG1, IgG2m4 (H268Q/V309L/A330S/P331S, changes to IgG4), and IgG4 ProAlaAla (S228P/L234A/L235A) in its capacity to bind FcγRs and activate various immune-stimulatory responses. In contrast to the previously characterized muted Fc variants, which retain selective FcγR binding and effector functions, IgG2σ shows no detectable binding to the Fcγ receptors in affinity and avidity measurements, nor any detectable antibody-dependent cytotoxicity, phagocytosis, complement activity, or Fc-mediated cytokine release. Moreover, IgG2σ shows minimal immunogenic potential by T-cell epitope analysis. The circulating half-life of IgG2σ in monkeys is extended relative to IgG1 and IgG2, in spite of similar in vitro binding to recombinant FcRn. The three-dimensional structure of the Fc, needed for assessing the basis for the absence of effector function, was compared with that of IgG2 revealing a number of conformational differences near the hinge region of the CH2 domain that result from the amino acid substitutions. Modeling reveals that at least one of the key interactions with FcγRs is disrupted by a conformational change that reorients P329 to a position that prevents it from interacting with conserved W90 and W113 residues of the FcγRs. Inspection of the structure also indicated significant changes to the conformations of D270 and P329 in the CH2 domain that could negatively impact C1q binding. Thus, structural perturbations of the Fc provide a rationale for the loss of function. In toto, these properties of IgG2σ suggest that it is a superior alternative to previously described IgG variants of minimal effector function, for future therapeutic applications of non-immunostimulatory mAb and Fc-fusion platforms.
Collapse
Affiliation(s)
- Omid Vafa
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States.
| | - Gary L Gilliland
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States.
| | - Randall J Brezski
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - Brandy Strake
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - Teresa Wilkinson
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - Eilyn R Lacy
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - Bernard Scallon
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - Alexey Teplyakov
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - Thomas J Malia
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| | - William R Strohl
- Biologics Research, Biotechnology Center of Excellence, Janssen Research & Development, LLC, 1400 McKean Road, Spring House, PA 19477, United States
| |
Collapse
|
16
|
Luo J, Obmolova G, Malia TJ, Wu SJ, Duffy KE, Marion JD, Bell JK, Ge P, Zhou ZH, Teplyakov A, Zhao Y, Lamb RJ, Jordan JL, San Mateo LR, Sweet RW, Gilliland GL. Lateral clustering of TLR3:dsRNA signaling units revealed by TLR3ecd:3Fabs quaternary structure. J Mol Biol 2012; 421:112-24. [PMID: 22579623 PMCID: PMC3920545 DOI: 10.1016/j.jmb.2012.05.006] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2012] [Revised: 04/27/2012] [Accepted: 05/03/2012] [Indexed: 12/19/2022]
Abstract
Toll-like receptor 3 (TLR3) recognizes dsRNA and initiates an innate immune response through the formation of a signaling unit (SU) composed of one double-stranded RNA (dsRNA) and two TLR3 molecules. We report the crystal structure of human TLR3 ectodomain (TLR3ecd) in a quaternary complex with three neutralizing Fab fragments. Fab15 binds an epitope that overlaps the C-terminal dsRNA binding site and, in biochemical assays, blocks the interaction of TLR3ecd with dsRNA, thus directly antagonizing TLR3 signaling through inhibition of SU formation. In contrast, Fab12 and Fab1068 bind TLR3ecd at sites distinct from the N- and C-terminal regions that interact with dsRNA and do not inhibit minimal SU formation with short dsRNA. Molecular modeling based on the co-structure rationalizes these observations by showing that both Fab12 and Fab1068 prevent lateral clustering of SUs along the length of the dsRNA ligand. This model is further supported by cell-based assay results using dsRNA ligands of lengths that support single and multiple SUs. Thus, their antagonism of TLR3 signaling indicates that lateral clustering of SUs is required for TLR3 signal transduction.
Collapse
Affiliation(s)
- Jinquan Luo
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Galina Obmolova
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Thomas J. Malia
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Sheng-Jiun Wu
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Karen E. Duffy
- Immunology Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - James D. Marion
- Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
| | - Jessica K. Bell
- Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
| | - Peng Ge
- Electron Imaging Center for Nanomachines (EICN), UCLA, Los Angeles, CA 90095, USA
| | - Z. Hong Zhou
- Electron Imaging Center for Nanomachines (EICN), UCLA, Los Angeles, CA 90095, USA
| | - Alexey Teplyakov
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Yonghong Zhao
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Roberta J. Lamb
- Immunology Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Jarrat L. Jordan
- Immunology Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Lani R. San Mateo
- Immunology Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Raymond W. Sweet
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| | - Gary L. Gilliland
- Biologics Research, Janssen Research and Development, L.L.C., 145 King of Prussia Road, Radnor, PA 19087, USA
| |
Collapse
|
17
|
Malia TJ, Obmolova G, Luo J, Teplyakov A, Sweet R, Gilliland GL. Crystallization of a challenging antigen-antibody complex: TLR3 ECD with three noncompeting Fabs. Acta Crystallogr Sect F Struct Biol Cryst Commun 2011; 67:1290-5. [PMID: 22102050 DOI: 10.1107/s1744309111030983] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2011] [Accepted: 08/02/2011] [Indexed: 12/31/2022]
Abstract
The mechanism of action of therapeutic antibodies can be elucidated from the three-dimensional crystal structures of their complexes with antigens, but crystallization remains the primary bottleneck to structure determination. Methods that resulted in the successful crystallization of TLR3 ECD in complex with Fab fragments from three noncompeting, neutralizing anti-TLR3 antibodies are presented. The crystallization of this 238 kDa complex was achieved through fine purification of the quaternary complex of TLR3 with the three Fab fragments combined with microseed matrix screening and additive screening. Fine purification entailed the application of a very shallow gradient in anion-exchange chromatography, resulting in the resolution of two separate complex peaks which had different crystallizabilities. Subsequent structure determination defined the epitopes of the respective antibodies and revealed a mechanistic hypothesis that is currently under investigation. The results also showed that cocrystallization with multiple noncompeting Fab fragments can be a viable path when an antigen complex with a single Fab proves to be recalcitrant to crystallization.
Collapse
Affiliation(s)
- Thomas J Malia
- Centocor R&D, 145 King of Prussia Road, Radnor, PA 19087, USA.
| | | | | | | | | | | |
Collapse
|
18
|
Malia TJ, Obmolova G, Almagro JC, Gilliland GL, Teplyakov A. Crystal structure of human germline antibody 3-23/B3. Mol Immunol 2011; 48:1586-8. [PMID: 21605907 DOI: 10.1016/j.molimm.2011.04.020] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2011] [Accepted: 04/22/2011] [Indexed: 10/18/2022]
Abstract
The human antibody repertoire is dominated by a few combinations of germline sequences, with the genes 3-23 for the heavy chain and B3 for the light chain being among the most frequently used. Despite this fact, there was no experimental structure of the antibody composed of 3-23 and B3. The crystal structure of the Fab fragment of the synthetic antibody composed of the 3-23 and B3 germline sequences was determined to provide a template for antibody modeling. The antigen-binding loops were found in the canonical conformations. Comparison to the other structures where either 3-23 or B3 is paired with a different chain reveals a significant deviation in the orientation of the variable domains.
Collapse
Affiliation(s)
- Thomas J Malia
- Centocor R&D, Inc., 145 King of Prussia Road, Radnor, PA 19087, USA
| | | | | | | | | |
Collapse
|
19
|
Wu B, Nemeth JF, Janecki DJ, Jones B, Obmolova G, Malia TJ, Baker A, Bethea D, Elloso MM, Naso M, Taudte S. Expression, refolding and purification of a human interleukin-17A variant. Cytokine 2010; 53:107-14. [PMID: 20674388 DOI: 10.1016/j.cyto.2010.07.002] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2010] [Revised: 06/30/2010] [Accepted: 07/02/2010] [Indexed: 10/19/2022]
Abstract
A human interleukin-17A (IL-17A) variant was overexpressed in Escherichia coli BL21 (DE3) under the control of a T(7) promoter. The resulting insoluble inclusion bodies were isolated and solubilized by homogenization with 6 M guanidine HCl. The denatured recombinant human IL-17A variant was refolded in 20 mM Tris-HCl, pH 9.0, 500 mM arginine, 500 mM guanidine HCl, 15% glycerol, 1 mM cystamine, and 5 mM cysteine at 2-8°C for 40 h. The refolded IL-17A variant was subsequently purified using a combination of cation-exchange, reversed-phase and fluoroapatite chromatography. The final purified product was a monodisperse and crystallizable homodimer with a molecular weight of 30,348.3 Da. The protein was active in both receptor binding competition assay and IL-17A-dependent biological activity assay using human dermal fibroblasts.
Collapse
Affiliation(s)
- Bingyuan Wu
- Biologics Research, Centocor Research and Development Inc., 145 King of Prussia Road, Radnor, PA 19087, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Obmolova G, Malia TJ, Teplyakov A, Sweet R, Gilliland GL. Promoting crystallization of antibody-antigen complexes via microseed matrix screening. Acta Crystallogr D Biol Crystallogr 2010; 66:927-33. [PMID: 20693692 PMCID: PMC2917276 DOI: 10.1107/s0907444910026041] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/08/2010] [Accepted: 07/01/2010] [Indexed: 11/24/2022]
Abstract
The application of microseed matrix screening to the crystallization of related antibodies in complex with IL-13 is described. Both self-seeding or cross-seeding helped promote nucleation and increase the hit rate. The application of microseed matrix screening to the crystallization of antibody–antigen complexes is described for a set of antibodies that include mouse anti-IL-13 antibody C836, its humanized version H2L6 and an affinity-matured variant of H2L6, M1295. The Fab fragments of these antibodies were crystallized in complex with the antigen human IL-13. The initial crystallization screening for each of the three complexes included 192 conditions. Only one hit was observed for H2L6 and none were observed for the other two complexes. Matrix self-microseeding using these microcrystals yielded multiple hits under various conditions that were further optimized to grow diffraction-quality H2L6 crystals. The same H2L6 seeds were also successfully used to promote crystallization of the other two complexes. The M1295 crystals appeared to be isomorphous to those of H2L6, whereas the C836 crystals were in a different crystal form. These results are consistent with the concept that the conditions that are best for crystal growth may be different from those that favor nucleation. Microseed matrix screening using either a self-seeding or cross-seeding approach proved to be a fast, robust and reliable method not only for the refinement of crystallization conditions but also to promote crystal nucleation and increase the hit rate.
Collapse
Affiliation(s)
- Galina Obmolova
- Centocor R&D, 145 King of Prussia Road, Radnor, PA 19087, USA.
| | | | | | | | | |
Collapse
|
21
|
Hiller S, Malia TJ, Garces RG, Orekhov VY, Wagner G. Backbone and ILV side chain methyl group assignments of the integral human membrane protein VDAC-1. Biomol NMR Assign 2010; 4:29-32. [PMID: 20437141 PMCID: PMC2896003 DOI: 10.1007/s12104-009-9194-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/05/2009] [Accepted: 10/27/2009] [Indexed: 05/24/2023]
Abstract
The voltage dependent anion channel (VDAC) forms a channel for metabolites and nutrients in the outer membrane of mitochondria, and it is also involved in apoptotic pathways. Here, we report sequence-specific NMR assignments for the isoform 1 of human VDAC reconstituted in lauryldimethylamine oxide (LDAO) detergent micelles. The assignments were deposited in the BMRB data base with accession number 16381.
Collapse
|
22
|
Fransson J, Teplyakov A, Raghunathan G, Chi E, Cordier W, Dinh T, Feng Y, Giles-Komar J, Gilliland G, Lollo B, Malia TJ, Nishioka W, Obmolova G, Zhao S, Zhao Y, Swanson RV, Almagro JC. Human framework adaptation of a mouse anti-human IL-13 antibody. J Mol Biol 2010; 398:214-31. [PMID: 20226193 DOI: 10.1016/j.jmb.2010.03.004] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2010] [Revised: 03/02/2010] [Accepted: 03/03/2010] [Indexed: 11/30/2022]
Abstract
Humanization of a potent neutralizing mouse anti-human IL-13 antibody (m836) using a method called human framework adaptation (HFA) is reported. HFA consists of two steps: human framework selection (HFS) and specificity-determining residue optimization (SDRO). The HFS step involved generation of a library of m836 antigen binding sites combined with diverse human germline framework regions (FRs), which were selected based on structural and sequence similarities between mouse variable domains and a repertoire of human antibody germline genes. SDRO consisted of diversifying specificity-determining residues and selecting variants with improved affinity using phage display. HFS of m836 resulted in a 5-fold loss of affinity, whereas SDRO increased the affinity up to 100-fold compared to the HFS antibody. Crystal structures of Fabs in complex with IL-13 were obtained for m836, the HFS variant chosen for SDRO, and one of the highest-affinity SDRO variants. Analysis of the structures revealed that major conformational changes in FR-H1 and FR-H3 occurred after FR replacement, but none of them had an evident direct impact on residues in contact with IL-13. Instead, subtle changes affected the V(L)/V(H) (variable-light domain/variable-heavy domain) interface and were likely responsible for the 5-fold decreased affinity. After SDRO, increased affinity resulted mainly from rearrangements in hydrogen-bonding pattern at the antibody/antigen interface. Comparison with m836 putative germline genes suggested interesting analogies between natural affinity maturation and the engineering process that led to the potent HFA anti-human IL-13 antibody.
Collapse
Affiliation(s)
- Johan Fransson
- Centocor R&D, Inc., 3210 Merryfield Row, San Diego, CA 92121, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Hiller S, Garces RG, Malia TJ, Orekhov VY, Colombini M, Wagner G. Solution structure of the integral human membrane protein VDAC-1 in detergent micelles. Science 2008; 321:1206-10. [PMID: 18755977 DOI: 10.1126/science.1161302] [Citation(s) in RCA: 545] [Impact Index Per Article: 34.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
The voltage-dependent anion channel (VDAC) mediates trafficking of small molecules and ions across the eukaryotic outer mitochondrial membrane. VDAC also interacts with antiapoptotic proteins from the Bcl-2 family, and this interaction inhibits release of apoptogenic proteins from the mitochondrion. We present the nuclear magnetic resonance (NMR) solution structure of recombinant human VDAC-1 reconstituted in detergent micelles. It forms a 19-stranded beta barrel with the first and last strand parallel. The hydrophobic outside perimeter of the barrel is covered by detergent molecules in a beltlike fashion. In the presence of cholesterol, recombinant VDAC-1 can form voltage-gated channels in phospholipid bilayers similar to those of the native protein. NMR measurements revealed the binding sites of VDAC-1 for the Bcl-2 protein Bcl-x(L), for reduced beta-nicotinamide adenine dinucleotide, and for cholesterol. Bcl-x(L) interacts with the VDAC barrel laterally at strands 17 and 18.
Collapse
Affiliation(s)
- Sebastian Hiller
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | | | | | |
Collapse
|
24
|
Takeuchi K, Ng E, Malia TJ, Wagner G. 1-13C amino acid selective labeling in a 2H15N background for NMR studies of large proteins. J Biomol NMR 2007; 38:89-98. [PMID: 17390105 DOI: 10.1007/s10858-007-9152-z] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/29/2006] [Accepted: 02/20/2007] [Indexed: 05/14/2023]
Abstract
Isotope labeling by residue type (LBRT) has long been an important tool for resonance assignments at the limit where other approaches, such as triple-resonance experiments or NOESY methods do not succeed in yielding complete assignments. While LBRT has become less important for small proteins it can be the method of last resort for completing assignments of the most challenging protein systems. Here we present an approach where LBRT is achieved by adding protonated (14)N amino acids that are (13)C labeled at the carbonyl position to a medium for uniform deuteration and (15)N labeling. This has three important benefits over conventional (15)N LBRT in a deuterated back ground: (1) selective TROSY-HNCO cross peaks can be observed with high sensitivity for amino-acid pairs connected by the labeling, and the amide proton of the residue following the (13)C labeled amino acid is very sharp since its alpha position is deuterated, (2) the (13)C label at the carbonyl position is less prone to scrambling than the (15)N at the alpha-amino position, and (3) the peaks for the 1-(13)C labeled amino acids can be identified easily from the large intensity reduction in the (1)H-(15)N TROSY-HSQC spectrum for some residues that do not significantly scramble nitrogens, such as alanine and tyrosine. This approach is cost effective and has been successfully applied to proteins larger than 40 kDa.
Collapse
Affiliation(s)
- Koh Takeuchi
- Department of Biochemistry and Molecular Pharmacology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
25
|
Abstract
Bcl-2 family proteins are essential regulators of cell death and exert their primary pro- or antiapoptotic roles at the mitochondrial outer membrane. Previously, pro- and antiapoptotic Bcl-2 proteins have been shown to interact with the voltage-dependent anion channel (VDAC) of the outer mitochondrial membrane. VDAC is a 283-residue integral membrane protein that forms an aqueous pore in the outer mitochondrial membrane, through which metabolites and other small molecules pass between the cytosol and intermembrane space. The essential life-sustaining function of VDAC in metabolite trafficking is believed to be regulated by proteins of the Bcl-2 family. The protective role of antiapoptotic Bcl-xL may be through its interaction with VDAC. Here, VDAC has been expressed, purified, and refolded into a functional form amenable to NMR studies. Various biophysical experiments indicate that micelle-bound VDAC is in intermediate exchange between monomer and trimer. Using NMR spectroscopy, gel filtration, and chemical cross-linking, we obtained direct evidence for binding of Bcl-xL to VDAC in a detergent micelle system. The VDAC-interacting region of Bcl-xL was characterized by NMR with chemical shift perturbation and transferred cross-saturation. The interaction region was mapped to a putative helical hairpin motif of Bcl-xL that was found to insert into detergent micelles. Our results suggest that Bcl-xL can bind to one or two VDAC molecules forming heterodimers and heterotrimers. Our characterization of the VDAC/Bcl-xL complex offers initial structural insight into the role of antiapoptotic Bcl-xL in regulating apoptotic events in the mitochondrial outer membrane.
Collapse
Affiliation(s)
- Thomas J. Malia
- Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Boston, MA 02115
- Massachusetts Institute of Technology, Department of Chemistry, Cambridge, MA 02139
| | - Gerhard Wagner
- Harvard Medical School, Department of Biological Chemistry and Molecular Pharmacology, Boston, MA 02115
| |
Collapse
|
26
|
Reibarkh M, Malia TJ, Hopkins BT, Wagner G. Identification of individual protein-ligand NOEs in the limit of intermediate exchange. J Biomol NMR 2006; 36:1-11. [PMID: 16964534 DOI: 10.1007/s10858-006-9028-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/15/2006] [Accepted: 05/03/2006] [Indexed: 05/11/2023]
Abstract
Interactions of proteins with small molecules or other macromolecules play key roles in many biological processes and in drug action, and NMR is an excellent tool for their structural characterization. Frequently, however, line broadening due to intermediate exchange completely eliminates the signals needed for measuring specific intermolecular NOEs. This limits the use of NMR for detailed structural studies in such kinetic situations. Here we show that an optimally chosen excess of ligand over protein can reduce the extent of line broadening for both the ligand and the protein. This makes observation of ligand resonances possible but reduces the size of the measurable NOEs due to the residual line broadening and the non-stoichiometric concentrations. Because the solubility of small molecule drug leads are often limited to high micromolar concentrations, protein concentrations are restricted to even lower values in the low micromolar range. At these non-stoichiometric concentrations and in the presence of significant residual line broadening, conventional NOESY experiments very often are not sensitive enough to observe intermolecular NOEs since the signals inverted by the NOESY preparation pulse sequence relax prior to significant NOE build up. Thus, we employ methods related to driven NOE spectroscopy to investigate protein-ligand interactions in the intermediate exchange regime. In this approach, individual protein resonances are selectively irradiated for up to five seconds to build up measurable NOEs at the ligand resonances. To enable saturation of individual protein resonances we prepare deuterated protein samples selectively protonated at a few sites so that the 1D (1)H spectrum of the protein is resolved well enough to permit irradiation of individual protein signals, which do not overlap with the ligand spectrum. This approach is suitable for measuring a sufficiently large number of protein-ligand NOEs that allow calculation of initial complex structures, suitable for structure-based optimization of primary drug leads obtained from high-throughput screening. The method was applied to measure individual intermolecular NOEs between the anti-apoptotic protein Bcl-xL at 25 microM and a "first generation" small-molecule ligand, for which the spectrum is entirely broadened at stoichiometric concentrations. This approach is general and can also be used to characterize protein-protein or protein-nucleic-acid complexes.
Collapse
Affiliation(s)
- Mikhail Reibarkh
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | | | | | | |
Collapse
|
27
|
Abstract
Identifying and characterizing small-molecule inhibitors of protein-protein interactions is of high interest for drug discovery and for chemical genetics studies of biological pathways. Very often, initial hits or first-generation compounds have low micromolar dissociation constants and cause line broadening in NMR spectra. It is very important for subsequent structure-based compound optimization to know if this line broadening is caused by intermediate exchange of the dissociation kinetics only or in addition by multiple binding modes. Here, we present an approach of how to distinguish these two situations and demonstrate its experimental application. Two very similar small-molecule ligands of Bcl-xL are considered that cause both severe line broadening of interface residues. We show that one compound exhibits single-mode binding, and broadening is just due to dissociation kinetics in the intermediate exchange regime, and the line broadening can be overcome by providing excess ligand. In the other case, line broadening is due to dissociation kinetics and exchange between multiple bound conformations, and broadening cannot be overcome by providing excess ligand. The procedures used are very general and can also be applied to characterizing protein-protein and protein-nucleic acid interactions.
Collapse
Affiliation(s)
- Mikhail Reibarkh
- Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | | | | |
Collapse
|
28
|
Walensky LD, Kung AL, Escher I, Malia TJ, Barbuto S, Wright RD, Wagner G, Verdine GL, Korsmeyer SJ. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science 2004; 305:1466-70. [PMID: 15353804 PMCID: PMC1360987 DOI: 10.1126/science.1099191] [Citation(s) in RCA: 1022] [Impact Index Per Article: 51.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
BCL-2 family proteins constitute a critical control point for the regulation of apoptosis. Protein interaction between BCL-2 members is a prominent mechanism of control and is mediated through the amphipathic alpha-helical BH3 segment, an essential death domain. We used a chemical strategy, termed hydrocarbon stapling, to generate BH3 peptides with improved pharmacologic properties. The stapled peptides, called "stabilized alpha-helix of BCL-2 domains" (SAHBs), proved to be helical, protease-resistant, and cell-permeable molecules that bound with increased affinity to multidomain BCL-2 member pockets. A SAHB of the BH3 domain from the BID protein specifically activated the apoptotic pathway to kill leukemia cells. In addition, SAHB effectively inhibited the growth of human leukemia xenografts in vivo. Hydrocarbon stapling of native peptides may provide a useful strategy for experimental and therapeutic modulation of protein-protein interactions in many signaling pathways.
Collapse
MESH Headings
- Alkenes
- Animals
- Apoptosis
- BH3 Interacting Domain Death Agonist Protein
- Bridged-Ring Compounds/chemical synthesis
- Bridged-Ring Compounds/chemistry
- Bridged-Ring Compounds/metabolism
- Bridged-Ring Compounds/pharmacology
- Carrier Proteins/chemistry
- Cell Division/drug effects
- Cell Line, Tumor
- Cell Membrane/metabolism
- Cytochromes c/metabolism
- Dose-Response Relationship, Drug
- Endosomes/metabolism
- Humans
- Jurkat Cells
- Leukemia, Experimental/drug therapy
- Leukemia, Experimental/pathology
- Leukemic Infiltration
- Mice
- Mice, SCID
- Mitochondria, Liver/drug effects
- Mitochondria, Liver/metabolism
- Molecular Mimicry
- Neoplasm Transplantation
- Peptide Fragments/chemistry
- Peptides/chemical synthesis
- Peptides/chemistry
- Peptides/metabolism
- Peptides/pharmacology
- Protein Binding
- Protein Engineering
- Protein Structure, Secondary
- Protein Structure, Tertiary
- Proto-Oncogene Proteins/chemistry
- Proto-Oncogene Proteins c-bcl-2/metabolism
- Transplantation, Heterologous
Collapse
Affiliation(s)
- Loren D Walensky
- Howard Hughes Medical Institute, Department of Pediatric Hematology/Oncology and Children's Hospital Boston, Massachusetts, USA
| | | | | | | | | | | | | | | | | |
Collapse
|